Kasparkova Jana, Marini Victoria, Najajreh Yousef, Gibson Dan, Brabec Viktor
Institute of Biophysics, Academy of Sciences of the Czech Republic, CZ-61265 Brno, Czech Republic.
Biochemistry. 2003 May 27;42(20):6321-32. doi: 10.1021/bi0342315.
The global modification of mammalian and plasmid DNAs by novel platinum compounds, cis- or trans-[PtCl(2)(NH(3))(Am)], where Am = NH(3), nonplanar heterocycle piperidine, piperazine, or aromatic planar heterocycle 4-picoline, was investigated in cell-free media using various biochemical and biophysical methods. These modifications have been compared with the activity of these new compounds in several tumor cell lines including those resistant to antitumor cis-diamminedichloroplatinum(II) (cisplatin). The results show that the replacement of the NH(3) group in cisplatin by the heterocyclic ligands does not considerably affect the DNA binding mode of this drug. Cytotoxicity studies have revealed that the replacement lowers the activity of the platinum compound in both sensitive and resistant cell lines. It has been suggested that the reduced activity of these analogues of cisplatin is associated with some features of the damaged DNA and/or its cellular processing. Alternatively, the reduced activity of the analogues of cisplatin might also be due to the factors that do not operate directly at the level of the target DNA, such as intracellular platinum uptake. In contrast to the analogues of cisplatin, the replacement of one ammine group by the heterocyclic ligand in its clinically ineffective trans isomer (transplatin) results in a radical enhancement of its activity in tumor cell lines. Importantly, this replacement also markedly alters the DNA binding mode of transplatin. The results support the view that one strategy of how to activate the trans geometry in bifunctional platinum(II) compounds including circumvention of resistance to cisplatin may consist of a chemical modification of the ineffective transplatin that results in an increased stability of its intrastrand cross-links in double-helical DNA and/or in an increased efficiency to form interstrand cross-links.
利用各种生化和生物物理方法,在无细胞培养基中研究了新型铂化合物顺式或反式-[PtCl(2)(NH(3))(Am)]对哺乳动物和质粒DNA的整体修饰情况,其中Am = NH(3)、非平面杂环哌啶、哌嗪或芳香平面杂环4-甲基吡啶。已将这些修饰与这些新化合物在几种肿瘤细胞系中的活性进行了比较,包括对抗肿瘤顺式二氨二氯铂(II)(顺铂)耐药的细胞系。结果表明,用杂环配体取代顺铂中的NH(3)基团对该药物的DNA结合模式影响不大。细胞毒性研究表明,这种取代降低了铂化合物在敏感和耐药细胞系中的活性。有人认为,顺铂这些类似物活性降低与受损DNA的某些特征和/或其细胞处理过程有关。或者,顺铂类似物活性降低也可能是由于并非直接作用于靶DNA水平的因素,如细胞内铂摄取。与顺铂类似物相反,在其临床无效的反式异构体(反铂)中用杂环配体取代一个氨基团会使其在肿瘤细胞系中的活性显著增强。重要的是,这种取代也明显改变了反铂的DNA结合模式。这些结果支持这样一种观点,即激活双功能铂(II)化合物中反式构型(包括规避对顺铂的耐药性)的一种策略可能包括对无效反铂进行化学修饰,从而提高其在双螺旋DNA中链内交联的稳定性和/或形成链间交联的效率。